Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

Inclusion Criteria22

• ECOG performance status 0-1 or KPS ≥ 70%
• Age ≥ 18 years
• Endometrioid adenocarcinoma histologic diagnosis on endometrial biopsy or dilatation and curettage
• No evidence of extrauterine disease, or suspicious pelvic lymph nodes, or distant metastases, or cervical invasion on pre-operative conventional imaging studies (Pelvic +/- Abdomen CT or MRI or sonogram, or body PET scan) and physical examination (uterine confined by exam and imaging )
• Suitable candidate for surgery
• Planned surgical treatment including hysterectomy in combination with SLN biopsy and a bilateral salpingo-oophorectomy
• No history of second primary cancer (invasive or in situ) within the past 5 years, not including non-melanoma skin cancer
• Approved and signed informed consent
• No history of neoadjuvant chemotherapy or radiotherapy for endometrial cancer
• No history of prior pelvic or abdominal radiotherapy
• Study Cohort (n=182)
• A patient will be enrolled in the study cohort if all the following criteria are met:
• At surgery, the patient must undergo:
• Hysterectomy
• Bilateral salpingo-oophorectomy, unless already performed (including allowing unilateral salpingo-oophorectomy if unilateral salpingo-oophorectomy already performed)
• Bilateral pelvic SLN mapping (bilateral sentinel nodes are negative for malignancy)
• On the final pathologic report, the patient must have a diagnosis of:
• Stage I intermediate-risk endometrial endometrioid cancer (Grade 1 or Grade 2 with ≥ 50% myometrial invasion or Grade 3 with \<50% myometrial invasion, including non-invasive disease)
• Negative pelvic peritoneal cytology
• Adjuvant treatment as recommended by the multidisciplinary team must be as follows:
• No adjuvant treatment, or
• Intravaginal radiation only